Season 8, Post 19: Why we die

“More book recommendations please” was the feedback from one Blog reader after post #11 where we profiled James Lovelock’s Novacene and its implications for the AI thematic. Longevity is another topic on which we have written extensively. The work Why We Die by Nobel Prize winner Venki Ramakrishnan provides many useful perspectives on the subject.

At its core, Ramakrishnan’s thesis is both sobering and strangely reassuring: ageing is not a problem to be ‘solved’ in the conventional sense, but rather a by-product of how evolution has optimised life. Biology prioritises reproduction and early survival, not long-term maintenance. Over time, the body accumulates damage at the molecular and cellular level, and the systems responsible for repair and renewal themselves degrade. In other words, death is not a failure of the system, but an inevitable feature of it. This stands in contrast to some of the more bullish narratives around radical life extension that have recently grown in prominence.

Yet this does not imply that nothing can be done. Quite the opposite. Ramakrishnan highlights that while there may be no single silver bullet, incremental advances in understanding biology are already delivering meaningful improvements in healthspan rather than lifespan. This aligns with our thesis that longevity is less about living forever and more about living better for longer.

At the same time, the book injects a note of caution into some of the more speculative corners of the theme. The complexity of human biology should not be underestimated. Interventions that target one pathway may create unintended consequences elsewhere. Moreover, there are important societal questions: what would materially longer lives mean for intergenerational equity, resource allocation and inequality? Technological improvement does not exist in a vacuum.

Ultimately, Why We Die reinforces the idea that the longevity theme is both powerful and nuanced. Progress is real, but likely to be evolutionary rather than revolutionary. As with many of the other themes we track, the winners may emerge not from those promising the most dramatic breakthroughs, but from those building the infrastructure – diagnostics, therapeutics and data – that enable better outcomes. Death, it seems, remains undefeated for now. But the journey towards delaying it – and improving the quality of life along the way – remains one of the most compelling frontiers of innovation.

27 May 2026

Please note, the Future Trends Blog will return in the second week of June once the Heptagon team is back from its annual firmwide offsite.

The above is provided for information purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Any forward looking statements are based on assumptions that may change. The views expressed are solely those of the author at the time of writing. This article should not be relied upon for investment decisions. Past performance does not predict future returns, the value of investments and income from them can fall as well as rise.

Photo by the author